JP2023539246A5 - - Google Patents

Info

Publication number
JP2023539246A5
JP2023539246A5 JP2023513297A JP2023513297A JP2023539246A5 JP 2023539246 A5 JP2023539246 A5 JP 2023539246A5 JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023539246 A5 JP2023539246 A5 JP 2023539246A5
Authority
JP
Japan
Prior art keywords
use according
cancer
compound
formula
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539246A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047380 external-priority patent/WO2022046792A2/en
Publication of JP2023539246A publication Critical patent/JP2023539246A/ja
Publication of JP2023539246A5 publication Critical patent/JP2023539246A5/ja
Pending legal-status Critical Current

Links

JP2023513297A 2020-08-25 2021-08-24 腫瘍微小環境の遺伝的調節のための方法及び組成物 Pending JP2023539246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070173P 2020-08-25 2020-08-25
US63/070,173 2020-08-25
PCT/US2021/047380 WO2022046792A2 (en) 2020-08-25 2021-08-24 Methods and compositions for genetic modulation of tumor microenvironments

Publications (2)

Publication Number Publication Date
JP2023539246A JP2023539246A (ja) 2023-09-13
JP2023539246A5 true JP2023539246A5 (cg-RX-API-DMAC7.html) 2024-09-02

Family

ID=80355668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513297A Pending JP2023539246A (ja) 2020-08-25 2021-08-24 腫瘍微小環境の遺伝的調節のための方法及び組成物

Country Status (10)

Country Link
US (1) US20220110924A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203955A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539246A (cg-RX-API-DMAC7.html)
KR (1) KR20230057426A (cg-RX-API-DMAC7.html)
AU (1) AU2021333655A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003466A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190514A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002286A (cg-RX-API-DMAC7.html)
WO (1) WO2022046792A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4654979A1 (en) * 2023-01-25 2025-12-03 Huyabio International, LLC Methods and compositions comprising a cardio-tolerated hdac inhibitor
CN117357530A (zh) * 2023-11-07 2024-01-09 苏州大学附属儿童医院 Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem

Similar Documents

Publication Publication Date Title
US12428486B2 (en) Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
JP2024023317A (ja) 二重特異性抗体の組成物及びその使用方法
JP2023530408A (ja) Cd70指向性がん免疫療法のための遺伝子修飾されたナチュラルキラー細胞
CA3117419A1 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
JP2022507295A5 (cg-RX-API-DMAC7.html)
JP2017530694A5 (cg-RX-API-DMAC7.html)
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
AU2020271012A1 (en) Humanized anti-DLL3 chimeric antigen receptors and uses thereof
WO2020205331A1 (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
US20220162301A1 (en) Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
JP2022535410A (ja) Taciを標的とする抗体及びキメラ抗原受容体
CA3244124A1 (en) Anti-mesothelin antibodies and their uses
WO2021226321A2 (en) Anti-tumor associated antigen antibodies and uses thereof
WO2018132508A1 (en) Methods and compositions relating to ex vivo culture and modulation of t cells
US20230338422A1 (en) Engineering gamma delta t cells with interleukin-36 for immunotherapy
KR20240127523A (ko) 항-cntn4 항체 및 그의 용도
US20260109774A1 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
US20250136703A1 (en) Anti-il13ra2 antibodies and uses thereof
WO2025147472A1 (en) Anti-611-ctf p95her2 antibodies and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
WO2026015853A1 (en) Enhancing activity and persistence of car-nk cells for the treatment of cancer and autoimmune diseases
HK40117638A (en) Human antibodies against fap-alpha
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof
EP4608444A2 (en) Anti-egfrviii antibodies and uses thereof
EP4615501A1 (en) Anti-5t4 antibodies and uses thereof